Show simple item record

dc.contributor.authorErtesvåg, Nina Urke
dc.contributor.authorCox, Rebecca Jane
dc.contributor.authorJalloh, Sarah Larteley Lartey
dc.contributor.authorMohn, Kristin Greve-Isdahl
dc.contributor.authorBrokstad, Karl Albert
dc.contributor.authorTrieu, Mai Chi
dc.date.accessioned2023-01-02T10:14:33Z
dc.date.available2023-01-02T10:14:33Z
dc.date.created2022-09-26T09:06:06Z
dc.date.issued2022
dc.identifier.issn2059-0105
dc.identifier.urihttps://hdl.handle.net/11250/3040244
dc.description.abstractHistory of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses circulating from 1968 to 2018. We found that vaccination and infection elicited cross-reactive antibody responses, predominantly directed against newer or future strains. Childhood H3-priming increased the breadth and magnitude of back-boosted A/H3N2-specific antibodies in adults. Broader and more durable A/H3N2-specific antibodies were observed in repeatedly vaccinated adults than in children and previously unvaccinated adults. Our findings suggest that early A/H3N2 exposure and frequent seasonal vaccination could increase the breadth and seropositivity of antibody responses, which may improve vaccine protection against future viruses.en_US
dc.language.isoengen_US
dc.publisherNatureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSeasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 virusesen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumber67en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1038/s41541-022-00490-0
dc.identifier.cristin2055221
dc.source.journalnpj Vaccinesen_US
dc.relation.projectNorges forskningsråd: 284930en_US
dc.identifier.citationnpj Vaccines. 2022, 7, 67.en_US
dc.source.volume7en_US
dc.source.issue1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal